Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Nov
15
Today In Oncology
Treatment Advances, Predictive Biomarkers May Improve Urothelial Carcinoma Care
Are Young Patients With Cancer Discussing Fertility Preservation With Physicians?
Prostatectomy With or Without Postprostatectomy Radiotherapy and Long-Term HRQOL in Localized Prostate Cancer
In Case You Missed It: Roundup From ESMO Congress 2024
Exploring Issues in Oncofertility
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Conexiant Oncology Logo